A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors ; volume:31 ; number:2 ; day:15 ; month:12 ; year:2012 ; pages:409-416 ; date:4.2013
Investigational new drugs ; 31, Heft 2 (15.12.2012), 409-416, 4.2013
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Gordon, Michael S.
Mendelson, David S.
Gross, Mitchell
Uttenreuther-Fischer, Martina
Ould-Kaci, Mahmoud
Zhao, Yihua
Stopfer, Peter
Agus, David B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-012-9904-9
- URN
-
urn:nbn:de:101:1-2019060823320825478397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gordon, Michael S.
- Mendelson, David S.
- Gross, Mitchell
- Uttenreuther-Fischer, Martina
- Ould-Kaci, Mahmoud
- Zhao, Yihua
- Stopfer, Peter
- Agus, David B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study